NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor
Epigenetic modifiers of the histone deacetylase (HDAC) family are often dysregulated in cancer cells. Experiments with small molecule HDAC inhibitors (HDACi) have proven that HDACs are a vulnerability of transformed cells. We evaluated a novel hydroxamic acid-based HDACi (KH16; termed yanostat) in h...
Main Authors: | Ramy Ashry, Al-Hassan M. Mustafa, Kristin Hausmann, Michael Linnebacher, Susanne Strand, Wolfgang Sippl, Matthias Wirth, Oliver H. Krämer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/14/3650 |
Similar Items
-
Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma
by: Kishor Pant, et al.
Published: (2020-03-01) -
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
by: Siddhartha Das Pramanik, et al.
Published: (2022-08-01) -
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
by: Nikolaos Garmpis, et al.
Published: (2021-03-01) -
Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
by: Oliver H. Krämer, et al.
Published: (2022-05-01) -
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer
by: Dineo eKhabele
Published: (2014-05-01)